Abstract
Purpose of reviewOne of the most vexing problems for gastroenterologists is what actions to take after receiving a histological diagnosis of gastric intestinal metaplasia. We approach the problem by starting with suggesting a biopsy protocol that ensures obtaining the biopsies required for diagnosis, assessing the status of the gastric mucosa, and effective communication with the pathologist and patient.Recent findingsThe rediscovery and integration of the long history of gastric damage and repair resulting in pseudopyloric metaplasia (called SPEM) into the thinking of investigators working with animal models of gastric cancer has resulted in improved ability to separate changes associated with benign repair from those associated with inflammation-associated gastric carcinogenesis.SummaryGastric intestinal metaplasia is a potential reversible product of injury and repair and not directly connected with carcinogenesis. Intestinal metaplasia is a biomarker for prior gastric injury and repair. The risk of gastric cancer is best assessed in relation to the severity, extent, and, most importantly, the cause of the atrophic changes.
Original language | English (US) |
---|---|
Pages (from-to) | 535-543 |
Number of pages | 9 |
Journal | Current Opinion in Gastroenterology |
Volume | 35 |
Issue number | 6 |
DOIs | |
State | Published - Nov 1 2019 |
Keywords
- Helicobacter pylori
- atrophy
- autoimmune gastritis
- cancer
- gastric
- gastric biopsy
- injury and repair
- intestinal metaplasia
- pseudopyloric metaplasia
- risk assessment
- spasmolytic polypeptide-expressing metaplasia
ASJC Scopus subject areas
- Gastroenterology